Scientists Find Popular Vitamin Targets Visible Signs of Aging, Makes Skin Look Younger
Getting adequate levels of vitamin C may help fight signs of skin aging, according to recent findings.
Doctors explain how to get more of the essential vitamin in your diet.
Your skin protects your body from germs and other environmental hazards, but it gets weaker over time. That changes its appearance, leading to visible signs of aging, like wrinkles and fine lines. While you can't do anything to stop your skin from getting older, new research suggests that vitamin C may help skin look younger.
Specifically, having plenty of vitamin C in your diet may help to reactivate certain genes that control your skin's growth and repair. The study, which was published in the Journal of Investigative Dermatology, used lab-grown models designed to mimic human skin. In these models, the skin cells were exposed to air while being nourished underneath with a liquid nutrient designed to mimic the way your skin gets nutrients from your blood vessels.
Meet the experts: Gary Goldenberg, M.D., assistant clinical professor of dermatology at Icahn School of Medicine at Mount Sinai Hospital; Ife J. Rodney, M.D., founding director of Eternal Dermatology + Aesthetics
The researchers used vitamin C at different concentrations comparable to what would be transported from your bloodstream to the epidermis, which is the outermost layer of your skin. After seven days, the researchers discovered that the skin that was treated with vitamin C had a thicker epidermal cell layer without impacting the stratum corneum, which is the outer layer of skin made up of dead cells. After two weeks, the epidermis was thicker, while the outer layer of dead skin cells was thinner.
This suggests that vitamin C helps to boost the formation and division of keratinocytes, skin cells that move from deeper layers of the skin to the surface, the researchers explained. The researchers also found that skin samples that were treated with vitamin C had more cell proliferation, which is important for maintaining the skin's healthy barrier and creating a fresher look.
'Vitamin C is a promising molecule that can be used as a developing treatment for epidermal thinning, including in aging,' the researchers wrote in the conclusion.
The findings raise questions about the impact of vitamin C on skin. So, should we all be having more of it in our lives for a healthier, younger-looking complexion? Here's what dermatologists want you to keep in mind.
Vitamin C, a.k.a. L-ascorbic acid, is a water-soluble vitamin. Humans need to get vitamin C from food and supplements, making it a vital part of the diet, according to the National Institutes of Health (NIH).
Vitamin C plays a role in several areas of health, including biochemical reactions to support collagen and protein metabolism, per the NIH. Vitamin C also helps with wound healing and is an antioxidant that supports immune function.
Most adult women need 65 to 75 milligrams of vitamin C a day, while most adult men need 75 to 90 milligrams daily. While many adults in the U.S. get the recommended amounts of vitamin C daily from foods and drinks, some are more at risk of not getting enough than others, per the NIH. Those include:
People who smoke and are exposed to second-hand smoke.
People who eat a limited diet.
People with certain medical conditions, like severe malabsorption, certain types of cancer, and some forms of kidney disease.
When you eat or drink something with vitamin C, it's absorbed into your bloodstream and then transported to the skin, explains Gary Goldenberg, M.D., assistant clinical professor of dermatology at Icahn School of Medicine at Mount Sinai Hospital. There, it tends to be concentrated in the basal layer of the epidermis, which is the deepest layer of the outer layer of your skin.
Vitamin C is a co-factor (meaning it's a required element) in a process that activates genes that are involved in cell proliferation, Dr. Goldenberg says. 'This can lead to epidermal thickening and improved skin health and appearance,' he says.
Vitamin C is also crucial for the production of collagen, a protein that helps to support your skin's barrier and enhances your skin's elasticity, says Ife J. Rodney, M.D., founding director of Eternal Dermatology + Aesthetics. 'Collagen is the building block of the skin,' she says. 'It's the supporting matrix that gives the skin its tightness and firmness, but over the years, it starts to break down. That's why skin gets saggy and thin.'
While having more vitamin C in your life won't magically transform your skin, it can help, Dr. Rodney says.
If you eat a lot of vitamin C-rich foods, Dr. Goldenberg says you should get enough of the nutrient to support good skin health. If you could do better, these are some of the most vitamin C-rich foods to consider eating, per the NIH:
Red bell pepper, ½ cup: 95 milligrams
Orange juice, ¾ cup: 93 milligrams
Orange, 1 medium: 70 milligrams
Grapefruit juice, ¾ cup: 70 milligrams
Kiwifruit, 1 medium: 64 milligrams
Green pepper, ½ cup: 60 milligrams
Broccoli, ½ cup: 51 milligrams
If you're not sure how you're doing on the vitamin C front or if you're concerned that you may not be absorbing the nutrient properly, Dr. Goldenberg says a blood test can help determine your levels. 'If levels are low or not optimal, supplementation can help,' he says. However, Dr. Rodney points out that vitamin C supplements aren't for everyone. 'They really don't help unless you're deficient,' she says.
This study focused on having vitamin C in your diet, but dermatologists say there's a role for vitamin C serums in skincare, too.
'I like topical vitamin C on the skin—serums, specifically,' Dr. Rodney says. Because of vitamin C's antioxidant effect, these can help to protect the skin from environmental stressors, she says, which may contribute to signs of aging. (Dr. Rodney recommends looking for a serum with vitamin C and ferulic acid, which helps keep the vitamin C molecule stable in your products.)
Overall, dermatologists say the findings stress the importance of eating a healthy diet for good skin health. 'Nutrition has a direct impact on skin health,' Dr. Goldenberg says. 'Nutrients like vitamin C can promote skin regeneration, delay aging effects, and maintain barrier function.'
Dietary supplements are products intended to supplement the diet. They are not medicines and are not intended to treat, diagnose, mitigate, prevent, or cure diseases. Be cautious about taking dietary supplements if you are pregnant or nursing. Also, be careful about giving supplements to a child, unless recommended by their healthcare provider.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
From Home Visits to Health Victories: Global Health Tech Gets Personal
Meet the health workers using tech to overcome deadly diseases NORTHAMPTON, MA / / August 19, 2025 / "Thank you so much for coming to my home. You saved my life." Those simple words from Bill Adams* spoke volumes to Karen Fernandez, one of the original community health workers with an in-home healthcare program called Healthy Neighbor in Camden, New Jersey. A few days before, she had met Bill for the first time at his home and discovered that his blood pressure was incredibly high. She called the triage line and was able to get him into the emergency department the same day. Before that first visit, Bill called Karen to ask if she was really going to show up. He didn't have health insurance or much trust in the healthcare system that had let him down so many times before. Karen did show up - the first step in creating trust and a foundation toward Bill's future health. "That's why I do this job," said Fernandez. "It's rewarding. If you can make an impact on a person's life, they will never forget it." This is just one of hundreds of stories illustrating the impact that the four community health workers who comprise Healthy Neighbor are bringing to the Camden community. They are equipped with a technology platform called SPICE from Medtronic LABS, which develops community-based, tech-supported healthcare solutions for underserved communities. This digital tool streamlines their work by capturing basic healthcare needs, tracking blood pressure and glucose over time, and flagging elevated readings for follow-up. This helps link community and health system care, reduces paperwork, and allows the community health workers to focus on their patients. Bringing a global program home Camden, a city of about 70,000 people across the Delaware River from Philadelphia, has a life expectancy gap of as much as 16 years compared to neighborhoods just 6.5 miles away.[i] The rates of diabetes and high blood pressure are dramatically higher than in nearby communities. Virtua Health is South Jersey's largest healthcare provider, and many of its patients live in Camden. When leadership at Virtua saw these staggering health statistics, they felt compelled to do something. "Our mission is to help our community be well, get well, and stay well. We take it very seriously," said Dan Master, the director of community health and impact at Virtua. "And there is a lot of alignment with Medtronic LABS and Medtronic in this." For over a decade, Medtronic LABS has built community-based, tech-enabled solutions to address healthcare disparities around the world. But they had never built a program in the United States. Until Virtua called. "When we first met with Virtua, we knew this was a great opportunity to bring our learnings from community-based care models in Asia and Africa to the U.S. and continue to innovate," said Lauren Leccese, head of U.S. programs at Medtronic LABS. "The shared values and commitment to health equity across our organizations created a strong foundation as we started to build the program." From pilot to expansion In August 2023, Medtronic LABS and Virtua launched Healthy Neighbor. The goal was to improve health outcomes through a home visiting program where community health workers provide integrated health and social care for patients living with high blood pressure and/or type 2 diabetes. And it's working. The data from the first two years of the program is in - and it's remarkable: 74% of patients with uncontrolled hypertension achieved meaningful improvement (15-point mean drop in systolic blood pressure) 69% of patients with uncontrolled diabetes achieved meaningful improvements (1.2% mean drop in A1C) These numbers are so impressive that the program is expanding. Virtua received a grant from the city of Camden to grow the community health worker team and reach more patients. "We all had high standards and high hopes for the program when it started, and it's been living up to them," said Alexis Nieves, a Healthy Neighbor community health worker who has been with the program from the beginning. "And these results are not just because of us, but because the patients are willing to make changes as well." More than the numbers The impact of Healthy Neighbor goes beyond data. Patients are enrolled in the program because of either uncontrolled high blood pressure or diabetes (or both), but the care they receive goes far beyond treating those conditions. "It's not normal for a medical team to go out of their way to help you," said Greg Ashton*, a Healthy Neighbor patient. "They're going above and beyond their duty, for someone that they don't even know." There are many factors that influence a person's health, and community health workers are skilled at addressing all of them. They help their patients secure housing, healthy food, heat, and mental-health support. They provide education on nutrition, teach patients to monitor their blood pressure and glucose levels, remind them about upcoming appointments, and help them find transportation to the appointments. "La Shawn is a positive influence on my life, she motivates me," said Denise Manlius, a Healthy Neighbor patient, of her community health worker. "She makes sure that I take my medications. She calls to remind me of appointments. She helped me change my eating habits. Since she's been in my life, my A1C (blood sugar) went down. And it's not just a paycheck to her; she really cares about her people." 'Someone cared enough' "A lot of patients just need to know someone cared enough," said La Shawn Dutton-Spruill. "To show them how to fill up their pillbox until they understand how to do it themselves. To help them understand that their meds will be green this month and white next month, but that it's still the same medication." Due to the program's success and a desire to replicate it to help more patients across the country, Virtua and Medtronic LABS created a toolkit that other health systems can use to establish Healthy Neighbor programs in their communities. The goal is to help more healthcare systems address health disparities and make a meaningful difference in the health of their patients and communities. As Fanny Ochoa, a community health worker with Healthy Neighbor, explained, "It's not just what you do when you're with the patient. The reward is seeing your patients continue to make changes after you leave. The goal of our work is to create a better lifestyle and a better outcome for our patients, beyond the time that we are with them." *Names changed to protect patient privacy Learn more about how Medtronic LABS develops community-based, tech-enabled solutions for underserved patients, families, and communities across the world. View additional multimedia and more ESG storytelling from Medtronic on Contact Info:Spokesperson: MedtronicWebsite: info@ SOURCE: Medtronic View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift
Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company's largest shareholder. The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business. The medtech giant is scheduled to host an Investor Day in mid-2026, as first reported by The Wall Street reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23. 'We're confident and well-positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers,' said Geoff Martha, Medtronic chairman and CEO. Cardiovascular Portfolio revenue of $3.285 billion increased 9.3% as reported and 7.0% organic, with a high-single digit increase in Cardiac Rhythm & Heart Failure, mid-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis. Neuroscience Portfolio revenue of $2.416 billion increased 4.3% reported and 3.1% organic, with a high-single digit increase in Neuromodulation and mid-single digit increase in Cranial & Spinal Technologies, offset by a low-single digit decrease in Specialty Therapies. View more earnings on MDT Medical Surgical Portfolio revenue of $2.083 billion grew 4.4% as reported and 2.4% organic, with low-single digit organic growth in both Surgical & Endoscopy and Acute Care & Monitoring. Diabetes business revenue of $721 million increased 11.5% as reported and 7.9% organic. Outlook Medtronic reiterates its fiscal year 2026 organic revenue growth guidance of 5%. The company revised its fiscal 2026 revenue growth on a reported basis from 4.8%-5.1% to 6.5%-6.8%. It raised sales guidance from $35.15 billion-$35.25 billion to $35.72 billion-$35.82 billion versus the consensus of $35.32 billion. Excluding the potential impact from tariffs, Medtronic expects underlying fiscal 2026 adjusted EPS growth to be approximately 4.5% versus the prior guidance of approximately 4%. Including the reduced potential impact from tariffs of approximately $185 million versus the prior range of roughly $200 million to $350 million, Medtronic raised its fiscal 2026 adjusted earnings to $5.60-$5.66 from the prior range of $5.50-$5.60 versus the consensus of $5.55. In July, a federal appeals court sided with Medtronic in a long-running patent dispute, reversing a jury's finding that the company induced infringement of a Colibri Heart Valve LLC patent related to the implantation of artificial heart valves. Price Action: MDT stock is trading lower by 2.00% to $90.95 premarket at last check Tuesday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MEDTRONIC (MDT): Free Stock Analysis Report This article Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors. Douglas Williams, Ph.D., brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). He has contributed to the development of several blockbuster therapies, including Enbrel®, Tecfidera® and Spinraza®. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences. Dr. Williams currently serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics. Adam Craig, M.D., Ph.D., is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma leading to the approval and commercialization of Vonjo®. He is currently Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). Dr Craig previously held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals and currently serves on the board of Stratus Therapeutics. Dr. Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School. "Doug and Adam are highly accomplished leaders whose deep expertise across R&D, commercialization, and corporate strategy will be invaluable as we advance our development candidates, EGEN-2784 for kidney failure and EGEN-5784 for liver failure, into the clinic," said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. "Their guidance will be invaluable as we advance into the next phase of growth as a clinical-stage company focused on our mission to transform the treatment of organ failure." "eGenesis is developing truly pioneering solutions for one of the most pressing unmet needs in medicine," said Dr. Williams. "The combination of cutting-edge genetic engineering, rigorous science, and a mission-driven team positions eGenesis to deliver breakthroughs that could fundamentally change the field of organ transplantation." "eGenesis is leading a field with the potential to transform the future of transplantation," added Dr. Craig. "I look forward to supporting the company's mission to develop safe, effective, human-compatible organs that could redefine the treatment of organ failure and offer hope to millions of patients awaiting a transplant." Drs. Williams and Craig join current Board members Steven Gillis, Ph.D. (Board Chairman), Bob More, Fabio Pucci, Ph.D., Brad Smith, Julie Sunderland, and Albert (Al) Wiegman. About eGenesis eGenesis is pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. Its platform uniquely addresses cross-species molecular incompatibilities and viral risk via its proprietary genetic engineering platform to improve outcomes for patients in need of a transplant. With demonstrated preclinical success, eGenesis is advancing programs in kidney transplantation, acute liver failure, and heart transplantation. Learn more at Follow us @egenesisbio. View source version on Contacts MediaKimberly Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data